Merrimack Pharmaceuticals
MACK
$14.98
Share price
1.63%
Change (1 day)
18.98%
Change (1 year)
Categories
Merrimack Pharmaceuticals (MACK) - Total debt
Total debt on the balance sheet as of March 2019 : $16.59 M
According to Merrimack Pharmaceuticals's latest financial reports the company's total debt is $16.59 M. A company’s total debt is the sum of all current and non-current debts.
Merrimack Pharmaceuticals - Total debt on balance sheet (from 2010 to 2019)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2018-12-31 | $14.87 M | |
| 2017-12-31 | $N/A | -100% |
| 2016-12-31 | $0.21 B | -15.83% |
| 2015-12-31 | $0.25 B | 114.71% |
| 2014-12-31 | $0.12 B | 7.46% |
| 2013-12-31 | $0.11 B | 180.2% |
| 2012-12-31 | $39.85 M | 82931.25% |
| 2011-12-31 | $0.04 M | -90.22% |
| 2010-12-31 | $0.49 M | -63.76% |
| 2009-12-31 | $1.35 M |
Total debt for similar companies or competitors
| Company | Total debt | differencediff. | Country |
|---|---|---|---|
 Sanofi SNY | $20.36 B | 122,600.77% | 🇫🇷 France |
 Geron GERN | $85.89 M | 417.50% | 🇺🇸 USA |
 Clovis Oncology CLVS | $0.68 B | 4,000.37% | 🇺🇸 USA |
 AVEO Oncology
AVEO | $38.68 M | 133.03% | 🇺🇸 USA |
 Eterna Therapeutics ERNA | $41.84 M | 152.08% | 🇺🇸 USA |